The Readout Loud 226: Pharma's telehealth gold mine, the return of the biotech IPO, & a merger deferred
Sep 15, 2022
Chapters
Transcript
Episode notes
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Introduction
00:00 • 2min
Biotechnology and Biomanufacturing Initiative
02:10 • 2min
Is $2 Billion a Big Start?
04:18 • 2min
Biotech IPO - Third Harmonic Bio
06:35 • 2min
Is This an IPO or a VC Backed Company?
08:08 • 2min
Amgen K-Ras Targeted Lung Cancer Drug
10:01 • 2min
Seagen's Stock Price Slipped Below $140 for the First Time in a Month
11:51 • 2min
Merck Acquisition of Seagen
13:29 • 2min
JP Morgan Healthcare Conference in San Francisco
15:12 • 2min
Is This Your First JP Morgan Healthcare Conference?
16:55 • 2min
Telehealth
18:40 • 2min
Telehealth - What's the Business Model?
20:12 • 3min
Is Direct-to-Consumer Telehealth Driving Prescription Drugs?
22:45 • 2min
Is There a Future for Telehealth?
24:20 • 3min